# Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

Source: https://onco.cc/trials/nct05329532/  
OnCo record `nct05329532` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in triple-negative breast cancer, renal cell carcinoma, ovarian cancer and head and neck squamous cell carcinoma, run by Scancell Ltd, now recruiting.

## Summary

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer is a phase 1/2 interventional study registered as NCT05329532 by Scancell Ltd, with 168 participants planned, started 2022-04-07 and due to reach its primary completion in 2026-07-01. Interventions recorded: Modi-1 Moditope, Pembrolizumab and MicronJet600™ microneedle device (NanoPass).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05329532
- Phase: 1/2
- Setting: A Phase 1/2, Multicentre, Open-Label Study of Modi-1 Moditope in Patients With Breast, Head and Neck, Ovarian, or Renal Cancer
- Sponsor: Scancell Ltd
- Enrolled: 168

## Sources

- ClinicalTrials.gov NCT05329532: https://clinicaltrials.gov/study/NCT05329532

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Scancell](https://onco.cc/companies/scancell/)

---
JSON: https://onco.cc/api/v1/entities/nct05329532.json